According to filings with the U.S. Securities and Exchange Commission, Renovion is raising $15,048,489.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Dan Copeland played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Renovion
Renovion is a clinical-stage company dedicated to advancing therapies that restore lung health. Our product, ARINA1, has been developed to change the lives of individuals with a lung transplant, non-cystic fibrosis bronchiectasis (NCFBE), non-tuberculous mycobacteria-lung disease (NTM-LD), and Tracheostomy. ARINA-1 has been shown to not only restore mucociliary clearance and ciliary function and expression, but also downregulate inflammation. It also has a potent secondary antibacterial mechanism that helps protect the lungs from bacterial growth. ARINA-1 restores lung health by clearing mucus, downregulating inflammation, and inhibiting bacterial growth. Individuals who have used ARINA·1 report significantly improved quality of life and decreased mucus burden. Renovion is targeting three main indications: prevention of bronchiolitis obliterans (BOS) progression in bilateral lung transplant, non-CF bronchiectasis (NCFBE), and non-tuberculous mycobacteria-lung disease (NTM-LD). ARINA-1 is a next generation mucolytic that can improve people’s lives and change the course of their disease.

To learn more about Renovion, visit http://www.renovion.com/

Contact:
Dan Copeland, Chief Executive Officer
919-240-7034
https://www.linkedin.com/in/dancopeland/

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.